Side-by-side · Research reference
AdipotidevsCartalax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BAnimal-MechanisticHUMAN-REVIEWED10/32 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
01Mechanism of Action
Parameter
Adipotide
Cartalax
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
—
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
Cartalax
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
—
Frequency
Not specified in available data
—
Evidence basis
Preclinical animal models only
Animal mechanistic studies only
Human data
None — no clinical trials reported
—
Animal model dose
—
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
Human dosing
—
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
Cartalax
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
Fat loss evidence
—
None — primary target is cartilage and bone tissue, not adipose
04Side Effects & Safety
Parameter
Adipotide
Cartalax
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Documented adverse effects
—
None reported in indexed animal studies
Human safety data
—
Not available in PubMed-indexed literature
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
Cartalax
- ·Unknown due to lack of human clinical trial data
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
05Administration Protocol
Parameter
Adipotide
Cartalax
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
—